1-11 of 11
James E Foley
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Changes in Prandial Glucagon Levels After a 2-Year Treatment With Vildagliptin or Glimepiride in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Monotherapy

Bo Ahrén, MD, PHD, James E. Foley, PHD, Ele Ferrannini, MD, David R. Matthews, MD, Bernard Zinman, MD, Sylvie Dejager, MD, PHD, Vivian A. Fonseca, MD, FRCP
Journal: Diabetes Care
Diabetes Care 2010;33(4):730–732
https://doi.org/10.2337/dc09-1867
Published: 12 January 2010
View article titled, Changes in Prandial Glucagon Levels After a 2-Year Treatment With Vildagliptin or Glimepiride in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Monotherapy
Open the PDF for Changes in Prandial Glucagon Levels After a 2-Year Treatment With Vildagliptin or Glimepiride in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Monotherapy in another window
Journal Articles

Dipeptidyl Peptidase-4 Inhibition by Vildagliptin and the Effect on Insulin Secretion and Action in Response to Meal Ingestion in Type 2 Diabetes

Chiara Dalla Man, PHD, Gerlies Bock, MD, Paula D. Giesler, RN, Denise B. Serra, PHARMD, Monica Ligueros Saylan, MD, James E. Foley, PHD, Michael Camilleri, MD, Gianna Toffolo, PHD, Claudio Cobelli, PHD, Robert A. Rizza, MD, Adrian Vella, MD
Journal: Diabetes Care
Diabetes Care 2009;32(1):14–18
https://doi.org/10.2337/dc08-1512
Published: 01 January 2009
View article titled, Dipeptidyl Peptidase-4 Inhibition by Vildagliptin and the Effect on Insulin Secretion and Action in Response to Meal Ingestion in Type 2 Diabetes
Open the PDF for Dipeptidyl Peptidase-4 Inhibition by Vildagliptin and the Effect on Insulin Secretion and Action in Response to Meal Ingestion in Type 2 Diabetes in another window
Journal Articles

Effects of the Dipeptidyl Peptidase-IV Inhibitor Vildagliptin on Incretin Hormones, Islet Function, and Postprandial Glycemia in Subjects With Impaired Glucose Tolerance

Julio Rosenstock, MD, James E. Foley, PHD, Marc Rendell, MD, Mona Landin-Olsson, MD, PHD, Jens J. Holst, MD, Carolyn F. Deacon, PHD, Erika Rochotte, MSC, Michelle A. Baron, MD
Journal: Diabetes Care
Diabetes Care 2008;31(1):30–35
https://doi.org/10.2337/dc07-1616
Published: 01 January 2008
View article titled, Effects of the Dipeptidyl Peptidase-IV Inhibitor Vildagliptin on Incretin Hormones, Islet Function, and Postprandial Glycemia in Subjects With Impaired Glucose Tolerance
Open the PDF for Effects of the Dipeptidyl Peptidase-IV Inhibitor Vildagliptin on Incretin Hormones, Islet Function, and Postprandial Glycemia in Subjects With Impaired Glucose Tolerance in another window
Includes: Supplementary data
Journal Articles

The Dipeptidyl Peptidase-4 Inhibitor Vildagliptin Improves β-Cell Function and Insulin Sensitivity in Subjects With Impaired Fasting Glucose

Kristina M. Utzschneider, MD, Jenny Tong, MD, MPH, Brenda Montgomery, RN, MS, Jayalakshmi Udayasankar, MD, Fernando Gerchman, MD, Santica M. Marcovina, PHD, Catherine E. Watson, PHD, Monica A. Ligueros-Saylan, MD, James E. Foley, PHD, Jens J. Holst, MD, Carolyn F. Deacon, PHD, Steven E. Kahn, MB, CHB
Journal: Diabetes Care
Diabetes Care 2008;31(1):108–113
https://doi.org/10.2337/dc07-1441
Published: 01 January 2008
View article titled, The Dipeptidyl Peptidase-4 Inhibitor Vildagliptin Improves β-Cell Function and Insulin Sensitivity in Subjects With Impaired Fasting Glucose
Open the PDF for The Dipeptidyl Peptidase-4 Inhibitor Vildagliptin Improves β-Cell Function and Insulin Sensitivity in Subjects With Impaired Fasting Glucose in another window
Journal Articles

Improved Meal-Related β-Cell Function and Insulin Sensitivity by the Dipeptidyl Peptidase-IV Inhibitor Vildagliptin in Metformin-Treated Patients With Type 2 Diabetes Over 1Year

Bo Ahrén, MD, PHD, Giovanni Pacini, PHD, James E. Foley, PHD, Anja Schweizer, PHD
Journal: Diabetes Care
Diabetes Care 2005;28(8):1936–1940
https://doi.org/10.2337/diacare.28.8.1936
Published: 01 August 2005
View article titled, Improved Meal-Related β-Cell Function and Insulin Sensitivity by the Dipeptidyl Peptidase-IV Inhibitor Vildagliptin in Metformin-Treated Patients With Type 2 Diabetes Over 1Year
Open the PDF for Improved Meal-Related β-Cell Function and Insulin Sensitivity by the Dipeptidyl Peptidase-IV Inhibitor Vildagliptin in Metformin-Treated Patients With Type 2 Diabetes Over 1Year in another window
Journal Articles

β-Cell Function in Mild Type 2 Diabetic Patients: Effects of 6-month glucose lowering with nateglinide

Andrea Mari, PHD, Amalia Gastaldelli, PHD, James E. Foley, PHD, Richard E. Pratley, MD, Ele Ferrannini, MD
Journal: Diabetes Care
Diabetes Care 2005;28(5):1132–1138
https://doi.org/10.2337/diacare.28.5.1132
Published: 01 May 2005
View article titled, β-Cell Function in Mild Type 2 Diabetic Patients: <subtitle>Effects of 6-month glucose lowering with nateglinide</subtitle>
Open the PDF for β-Cell Function in Mild Type 2 Diabetic Patients: <subtitle>Effects of 6-month glucose lowering with nateglinide</subtitle> in another window
Journal Articles

Addition of Nateglinide to Rosiglitazone Monotherapy Suppresses Mealtime Hyperglycemia and Improves Overall Glycemic Control

Vivian Fonseca, MD, George Grunberger, MD, Shamita Gupta, PHARMD, Sharon Shen, MS, James E. Foley, PHD
Journal: Diabetes Care
Diabetes Care 2003;26(6):1685–1690
https://doi.org/10.2337/diacare.26.6.1685
Published: 01 June 2003
View article titled, Addition of Nateglinide to Rosiglitazone Monotherapy Suppresses Mealtime Hyperglycemia and Improves Overall Glycemic Control
Open the PDF for Addition of Nateglinide to Rosiglitazone Monotherapy Suppresses Mealtime Hyperglycemia and Improves Overall Glycemic Control in another window
Journal Articles

Combination Therapy With Nateglinide and a Thiazolidinedione Improves Glycemic Control in Type 2 Diabetes

Julio Rosenstock, MD, Sharen G. Shen, MS, Marjorie R. Gatlin, MD, James E. Foley, PHD
Journal: Diabetes Care
Diabetes Care 2002;25(9):1529–1533
https://doi.org/10.2337/diacare.25.9.1529
Published: 01 September 2002
View article titled, Combination Therapy With Nateglinide and a Thiazolidinedione Improves Glycemic Control in Type 2 Diabetes
Open the PDF for Combination Therapy With Nateglinide and a Thiazolidinedione Improves Glycemic Control in Type 2 Diabetes in another window
Journal Articles

Importance of Early Insulin Secretion: Comparison of nateglinide and glyburide in previously diet-treated patients with type 2 diabetes

Priscilla A. Hollander, MD, PHD, Sherwyn L. Schwartz, MD, Marjorie R. Gatlin, MD, Stephen J. Haas, BS, Hongjie Zheng, BS, James E. Foley, PHD, Beth E. Dunning, PHD
Journal: Diabetes Care
Diabetes Care 2001;24(6):983–988
https://doi.org/10.2337/diacare.24.6.983
Published: 01 June 2001
View article titled, Importance of Early Insulin Secretion: <subtitle>Comparison of nateglinide and glyburide in previously diet-treated patients with type 2 diabetes </subtitle>
Open the PDF for Importance of Early Insulin Secretion: <subtitle>Comparison of nateglinide and glyburide in previously diet-treated patients with type 2 diabetes </subtitle> in another window
Journal Articles

Rationale and Application of Fatty Acid Oxidation Inhibitors in Treatment of Diabetes Mellitus

James E Foley, PHD
Journal: Diabetes Care
Diabetes Care 1992;15(6):773–784
https://doi.org/10.2337/diacare.15.6.773
Published: 01 June 1992
View article titled, Rationale and Application of Fatty Acid Oxidation Inhibitors in Treatment of Diabetes Mellitus
Open the PDF for Rationale and Application of Fatty Acid Oxidation Inhibitors in Treatment of Diabetes Mellitus in another window
Journal Articles

The Biologic Potency and Binding Affinity of Biosynthetic Human Insulin in Isolated Rat Adipocytes

Ole Sonne, James E Foley, Jørgen Gliemann
Journal: Diabetes Care
Diabetes Care 1981;4(2):250–251
https://doi.org/10.2337/diacare.4.2.250
Published: 01 March 1981
View article titled, The Biologic Potency and Binding Affinity of Biosynthetic Human Insulin in Isolated Rat Adipocytes
Open the PDF for The Biologic Potency and Binding Affinity of Biosynthetic Human Insulin in Isolated Rat Adipocytes in another window